An observational study in Age Related Macular Degeneration and Choroidal Neovascularization, sponsored by Notal Vision Ltd.. Withdrawn at 1 site in France. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2016-09-21.
Sponsored by Notal Vision Ltd. · Observational
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD). However, the device has the ability to detect the development of the lesion post treatment and therefore to assess in determination of the next treatment.
The Optical Coherence Tomography (OCT) may be used as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices.
The FORESEE HOME can be used as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluating the size and the location of the treated lesions may serve as an additional tool.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
Browse Macular Degeneration studies →Notal Vision Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
CNV subjects
For naïve CNV lesion - diagnosed in less than 60 days. OR For re-activated CNV lesion - treated more than 4 month from the diagnosis.
Exclusion Criteria:
Newly diagnosed CNV, before any treatment (naïve)
Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
Investigate the correlation between features of CNV lesions as measured with SD OCT and in the ForeseeHome.
the measures are Height of Pigment Epithelial Detachment , Sub Retinal Fluid Thickness , Maximum Diameter of Largest Retinal Cyst , Maximum Retinal Thickness , Central Retinal Thickness
Time frame: 3-4 months
This study is withdrawn, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Notal Vision Ltd.